A major clinical trial is offering new hope for patients battling one of the deadliest forms of cancer.

Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic ...

A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...

In a 36-patient trial, a vitamin D drug softened the wall around pancreatic tumors, letting chemotherapy and immune cells ...

A new experimental drug for metastatic pancreatic cancer nearly doubled overall survival in a ...

Two nights before the data were announced, “transformative” was the word used to describe the results for RASolute 302 ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...

Coming soon to Saint Anne's Hospital in Fall River: Oncology care branded with the diagnostic expertise, clinical trial variety, and options for chemotherapy—all from prestigious Dana-Farber Cancer ...

SAN DIEGO, April 17, 2026 — Dana-Farber Cancer Institute researchers will present more than 50 studies at the American Association for Cancer Research (AACR) Annual Meeting 2026, from April 17-22, in ...